source
- Eli Lilly makes 14th acquisition of 2026, buying a blood-cancer biotechEli Lilly announced it has acquired a blood‑cancer focused biotechnology company, marking its 14th acquisition in 2026. The deal reflects Lilly’s aggressive expansion strategy, funded by strong sa…
- Wave Life Sciences reports stronger weight-loss effect of WVE-007 in patients with higher BMI and excess body fatWave Life Sciences presented data at ObesityWeek 2026 from its mid-stage INLIGHT trial of the investigational siRNA drug WVE-007. The analysis of three cohorts showed that participants with higher…